County of Renfrew champions regional priorities at 2026 AMO Conference - County of Renfrew

Cold and flu season is upon us, and the Renfrew County and District Health Unit wants local families to be prepared. The RCDHU is encouraging parents and caregivers to take advantage of Ontario’s publicly funded Infant RSV Prevention program to protect their children against respiratory syncytial virus, which Medical Officer of Health Dr. Jason Morgenstern says can cause serious harm for infants and high-risk children. Families with infants born on or before April 1, 2026 and who are under 8 months old at the time of immunization and children under 24 months old who remain vulnerable to RSV are eligible for the program, which will run from October until March. The immunization will be available at hospitals for newborns prior to discharge, as well as at participating health care providers, obstetricians, and midwives. Appointments are also currently being booked for RCDHU-led immunization clinics which will start on October 21. The health unit is also encouraging parents and caregivers to ask their health care providers for a record of their children’s RSV immunization to keep for future visits.(written by Kasey Egan)

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.